Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Isis, Merck, Dicerna, and More

Premium

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer Using miR-17-3p

Patent Number: 8,377,637

Filed: March 30, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.”


Title: Compositions and Methods for Non-Parenteral Delivery of Oligonucleotides

Patent Number: 8,377,897

Filed: Sept. 28, 2005

Lead Inventor: Ching-Leou Teng, Isis Pharmaceuticals

The invention relates to “compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration,” according to the patent's abstract. “Pharmaceutical compositions comprising oligonucleotides ... include, for systemic delivery, emulsion, and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes. The compositions and methods of the invention are utilized to effect the oral, buccal, rectal, or vaginal administration of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative, or prophylactic purposes.”


Title: Composition for Treatment of Cervix Cancer

Patent Number: 8,377,899

Filed: Nov. 5, 2007

Lead Inventor: Young Kee Shin, Seoul National University

The invention relates to a “composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papillomavirus-specific siRNA as an active ingredient and the second active part containing an anti-cancer agent as an active ingredient,” the patent's abstract states. “The composition for the treatment of cancer of the present invention has better anti-cancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.”


Title: RNAi Compound Targeted to Thrombospondin-1 and Applications Thereof

Patent Number: 8,377,902

Filed: Jan. 6, 2011

Lead Inventor: Ming-Derg Lai, National Cheng Kung University

The invention, the patent's abstract states, comprises “an RNAi compound and an expression plasmid for inhibiting expression of thrombospondin-1, which comprises a target sequence selected from [the] thrombospondin-1 gene. The ... invention [is] also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of thrombospondin-1 to activate immune responses. In addition, the … RNAi compound … can delay tumor progression.”


Title: RNAi Compositions Comprising miR-34 Therapeutic Agents for Treating Cancer

Patent Number: 8,378,088

Filed: May 5, 2008

Lead Inventor: Michele Cleary, Merck

“The invention generally relates to compositions comprising miR-34, and siRNAs functionally and structurally related to miR-34 for the treatment of cancer,” according to the patent's abstract.


Title: miR-150 for the Treatment of Blood Disorders

Application Number: 20130039895

Filed: Oct. 16, 2012

Lead Inventor: Jun Lu, Massachusetts Institute of Technology

“The invention provides methods of treating certain blood-related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells, respectively,” the patent application's abstract states.


Title: Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics

Application Number: 20130039970

Filed: June 20, 2012

Lead Inventor: Barry Polisky, Marina Biotech

The invention, the patent application's abstract states, relates to “processes and compositions for liposomal delivery of therapeutical prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition.”


Title: Compositions and Methods for Inhibition of VEGF

Application Number: 20130039971

Filed: July 23, 2012

Inventor: Nadine Dejneka, Opko Health

The invention, the patent application's abstract states, comprises “siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor isoforms. Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering small interfering RNAs.”


Title: Compositions and Methods for the Specific Inhibition of Gene Expression by dsRNA Containing Modified Nucleotides

Application Number: 20130041010

Filed: Jan. 9, 2012

Inventor: Bob Brown, Dicerna Pharmaceuticals

“The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in eukaryotic cell,” according to the patent application's abstract.


Title: siRNA-Based Therapy of Fibrodysplasia Ossificans Progressiva

Application Number: 20130041017

Filed: Oct. 17, 2012

Lead Inventor: Frederick Kaplan, University of Pennsylvania

“This invention is directed to mutated activin A type I receptor proteins and isolated nucleic acids encoding same,” the patent application's abstract states. “The invention also relates to compositions and methods for siRNA-based regulation of mutated ACVR1 expression in the treatment of fibrodysplasia ossificans progressiva.”


Title: Novel Single-Chemical Entities and Methods for Delivery of Oligonucleotides

Application Number: 20130041133

Filed: April 4, 2011

Lead Inventor: Jeffery Aaronson, Merck

The invention relates to “a modular composition comprising an oligonucleotide; one or more linkers, which may be the same or different … [and] are attached to the oligonucleotide at any 3' and/or 5' end; one or more peptides, which may be the same or different ... [and are] are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide,” the patent application's abstract states.

The Scan

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SAR-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.